W. Kreuz

发表

Inhibitors in patients with haemophilia A.

C. E. Ettingshausen, W. Kreuz, C. Ettingshausen, 2014, Thrombosis research.

Inhibitors and prophylaxis in paediatric haemophilia patients: focus on the German experience.

G. Auerswald, K. Kurnik, W. Kreuz, 2014, Thrombosis research.

A review of immune tolerance induction with Haemate® P in haemophilia A

W. Kreuz, C. Escuriola Ettingshausen, C. Ettingshausen, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma‐derived or recombinant factor VIII concentrates: a systematic review

A. Iorio, M. Marcucci, E. Santagostino, 2010, Journal of thrombosis and haemostasis : JTH.

Efficacy, safety and tolerability of recombinant factor VIII (REFACTO®) in patients with haemophilia A: interim data from a postmarketing surveillance study in Germany and Austria

A. Ganser, J. Oldenburg, R. Klamroth, 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

Recombinant vs. plasma‐derived products, especially those with intact VWF, regarding inhibitor development

C. E. Ettingshausen, W. Kreuz, C. Ettingshausen, 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs

W. Kreuz, S. Ehrenforth, I. Scharrer, 1992, The Lancet.

High Titer Inhibitors in Severe Haemophilia A

F. Rosendaal, R. Ljung, J. Vermylen, 1994, Thrombosis and Haemostasis.

A common 253‐kb deletion involving VWF and TMEM16B in German and Italian patients with severe von Willebrand disease type 3

R. Marschalek, J. Oldenburg, G. Castaman, 2007, Journal of thrombosis and haemostasis : JTH.

Lack of HIV-1 V3 region sequence diversity in two haemophiliac patients infected with a putative biologic clone of HIV-1.

M. Gahr, R. Kurth, J. Löwer, 1991, AIDS.

Multicentre evaluation of combined prothrombotic defects associated with thrombophilia in childhood

R. Junker, W. Kreuz, U. Nowak‐Göttl, 1999, European Journal of Pediatrics.

Early long‐term FEIBA prophylaxis in haemophilia A patients with inhibitor after failing immune tolerance induction: A prospective clinical case series

C. E. Ettingshausen, W. Kreuz, C. Ettingshausen, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

Symptomatic Onset of Severe Hemophilia A in Childhood is Dependent on the Presence of Prothrombotic Risk Factors

R. Junker, K. Kurnik, W. Kreuz, 2001, Thrombosis and Haemostasis.

Platelet-dependent coagulation assays for factor VIII efficacy measurement after substitution therapy in patients with haemophilia A

W. Kreuz, M. Krause, I. Scharrer, 2006, Platelets.

2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema

P. Keith, J. Bernstein, R. Schellenberg, 2010, Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology.

Absence of anti-human immunodeficiency virus types 1 and 2 seroconversion after the treatment of hemophilia A or von Willebrand's disease with pasteurized factor VIII concentrate.

G. Auerswald, W. Schramm, W. Kreuz, 1989, The New England journal of medicine.

Immune status of HIV and HCV negative haemophiliacs treated with Intermediate- purity factor VIII concentrates

W. Kreuz, S. Ehrenforth, M. Funk, 1993, The Lancet.

Minor head injury as cause and co-factor in the aetiology of stroke in childhood: a report of eight cases

W. Kreuz, C. Heller, M. Kieslich, 2002, Journal of neurology, neurosurgery, and psychiatry.

Haemate P in children with von Willebrand's disease.

W. Kreuz, I. Scharrer, B. Kornhuber, 1994, Haemostasis.

Central Nervous System Involvement of Children with Hiv Nfection

J. Seeger, W. Kreuz, B. Schmitt, 1991 .

Hereditary and acquired angioedema: Problems and progress: Proceedings of the third C1 esterase inhibitor deficiency workshop and beyond

A. Tordai, L. Truedsson, M. López-Trascasa, 2004, Journal of Allergy and Clinical Immunology.

Prothrombotic risk factors in childhood stroke and venous thrombosis

W. Kreuz, I. Scharrer, C. Heller, 1999, European Journal of Pediatrics.

High expression of APO-1 (CD95) on T lymphocytes from human immunodeficiency virus-1-infected children.

A. Benner, P. Krammer, K. Debatin, 1994, Blood.

Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant).

P. Schlattmann, J. Frank, K. Bork, 2007, The Journal of allergy and clinical immunology.

Factor VII deficiency: clinical manifestation of 717 subjects from Europe and Latin America with mutations in the factor 7 gene

J. Astermark, S. Schulman, A. Batorova, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

Home Treatment in Patients with Hereditary Angiodema (HAE)

W. Kreuz, E. Aygören‐Pürsün, I. Martínez-Saguer, 2006 .

Individual Replacement Therapy (IRT) with a Pasteurized C1-Inhibitor Concentrate Compared to Prophylaxis with Danazol in Patients with Hereditary Angioedema (HAE) - A Prospective Study

W. Kreuz, E. Aygören‐Pürsün, I. Martínez-Saguer, 2006 .

Hereditary angiodema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema.

William H. Yang, P. Keith, R. Schellenberg, 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Canadian 2003 International Consensus Algorithm For the Diagnosis, Therapy, and Management of Hereditary Angioedema.

William H. Yang, H. Farkas, R. Warrington, 2004, The Journal of allergy and clinical immunology.

Effects of the factor V G1691A mutation and the factor II G20210A variant on the clinical expression of severe hemophilia A in children – results of a multicenter study

K. Kurnik, C. E. Ettingshausen, W. Kreuz, 2007 .

Effects of the factor V G1691A mutation and the factor II G20210A variant on the clinical expression of severe hemophilia A in children--results of a multicenter studys.

K. Kurnik, C. E. Ettingshausen, W. Kreuz, 2007, Haematologica.

Portal vein thrombosis in a patient with severe haemophilia A and F V G1691A mutation during continuous infusion of F VIII after intramural jejunal bleeding – Successful thrombolysis under heparin therapy

W. Kreuz, C. Escuriola Ettingshausen, I. M. Saguer, 1999, European Journal of Pediatrics.

Portal vein thrombosis in a patient with severe haemophilia A and F V G1691A mutation during continuous infusion of F VIII after intramural jejunal bleeding: Successful thrombolysis under heparin therapy : Haemophilia and von Willebrand disease

C. E. Ettingshausen, W. Kreuz, I. M. Saguer, 1999 .

Inhibitors in haemophilia A: the role of VWF/FVIII concentrates – a meeting report

S. Kaveri, A. Gringeri, W. Kreuz, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

The role of VWF for the success of immune tolerance induction.

W. Kreuz, 2008, Thrombosis research.

Role of von Willebrand factor in immune tolerance induction

C. E. Ettingshausen, W. Kreuz, C. Ettingshausen, 2005, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Epidemiology of inhibitors and current treatment strategies.

G. Auerswald, T. Klingebiel, C. E. Ettingshausen, 2003, Haematologica.

Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products.

J. Oldenburg, T. Klingebiel, C. E. Ettingshausen, 2002, Seminars in thrombosis and hemostasis.

Factor VIII Inhibitors in Patients with Hemophilia A: Epidemiology of Inhibitor Development and Induction of Immune Tolerance for Factor VIII

G. Auerswald, C. Escuriola-Ettingshausen, G. Auerswald, 1995, Seminars in thrombosis and hemostasis.

Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors.

A. von Eckardstein, R. Junker, W. Kreuz, 2001, Blood.

Thrombophilic disorders in children with cerebral infarction

W. Kreuz, I. Scharrer, C. Heller, 1998, The Lancet.

Haemate® P/Humate‐P® for the treatment of von Willebrand disease: considerations for use and clinical experience

G. Auerswald, W. Kreuz, 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

Human Immunodeficiency Virus-Negative ››High-Risk Patients‹‹ with Hemophilia or Severe von Willebrand Disease Type 3: Coincidence or Genetics?

G. Auerswald, W. Kreuz, R. Linde, 2001 .

Immune tolerance therapy in paediatric haemophiliacs with factor VIII inhibitors: 14 years follow‐up

G. Auerswald, W. Kreuz, S. Ehrenforth, 1995, Haemophilia : the official journal of the World Federation of Hemophilia.

549 Management of Twenty-Five Pediatric Patients with Hereditary Angioedema (Hae) Undergoing Home Treatment—A Clinical Surveillance Program

T. Klingebiel, W. Kreuz, E. Aygören‐Pürsün, 2012, The World Allergy Organization Journal.

Coagulation Factor XIII Mutation Profile: Update 2004

E. Seifried, J. Oldenburg, V. Ivaškevičius, 2006 .

Combined Heterozygous Factor XIII-Deficiency in a Family Case Report

J. Oldenburg, V. Ivaškevičius, C. E. Ettingshausen, 2005 .

Immune tolerance induction with mycophenolate‐mofetil in two children with haemophilia B and inhibitor

W. Kreuz, M. Funk, C. Heller, 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

Therapie hereditärer Thrombozytopathien

R. Zotz, U. Scholz, W. Kreuz, 2014, Hämostaseologie.

[Therapy of inherited diseases of platelet function. Interdisciplinary S2K guideline of the Permanent Paediatric Committee of the Society of Thrombosis and Haemostasis Research (GTH e. V.)].

R. Zotz, U. Scholz, W. Kreuz, 2014, Hamostaseologie.

Multicentre Evaluation of Combined Prothrombotic Defects in Childhood Thromboembolism

W. Kreuz, U. Nowak‐Göttl, S. Ehrenforth, 1999 .

Ophthalmic manifestation of congenital protein C deficiency.

W. Kreuz, L. Hattenbach, T. Beeg, 1999, Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus.

Inherited defects of the protein C anticoagulant system in childhood thrombo-embolism

W. Kreuz, U. Nowak‐Göttl, U. Göbel, 1996, European Journal of Pediatrics.

Replacement Therapy with a Monoclonal Antibody Purified Protein C Concentrate in Newborns with Severe Congenital Protein C Deficiency

M. Dreyfus, J. Cohen, G. Rivard, 1995, Seminars in thrombosis and hemostasis.

Heterozygous prothrombin gene mutation: a new risk factor for early renal allograft thrombosis.

B. Tönshoff, F. Schaefer, W. Kreuz, 1999, Transplantation.

Combined therapy in human immunodeficiency virus-infected children —a 4-year experience

W. Kreuz, S. Ehrenforth, R. Linde, 1993, European Journal of Pediatrics.

Replacement Therapy with Protein C Concentrate in Infants and Adolescents with Meningococcal Sepsis and Purpura Fulminans

C. E. Ettingshausen, W. Kreuz, T. Beeg, 1999, Seminars in thrombosis and hemostasis.

Need for therapeutic drug monitoring in HIV-1 infected children receiving efavirenz doses according to international guidelines.

W. Kreuz, R. Linde, M. Funk, 2006, European journal of medical research.

Rapid development of giant aneurysm at the base of the brain in an 8-year-old boy with perinatal HIV infection.

H. Hacker, W. Kreuz, G. Herrmann, 1992, Acta histochemica. Supplementband.

Association of ABO(H) and I blood group system development with von Willebrand factor and Factor VIII plasma levels in children and adolescents

E. Seifried, T. Klingebiel, C. Geisen, 2010, Transfusion.

Post-trauma coagulation and fibrinolysis in children suffering from severe cerebro-cranial trauma

W. Kreuz, U. Nowak‐Göttl, I. Scharrer, 1999, European journal of pediatrics.

Multimerization of Peptide Mimotopes for Blocking of Factor VIII Neutralizing Antibodies

U. Dietrich, C. Königs, T. Klingebiel, 2009, ChemMedChem.

Seroprevalence of HCV, HAV, HBV, HDV, HCMV and HIV in high risk groups/Frankfurt a.M., Germany.

S. Staszewski, H. Doerr, A. Berger, 1995, Zentralblatt fur Bakteriologie : international journal of medical microbiology.

Pharmacokinetic properties of a pasteurised fibrinogen concentrate.

W. Kreuz, S. Haertel, E. Meili, 2005, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

Elevated Factor VIIIC: Ag in Children with Venous Thrombosis and Stroke — Preliminary Results of a Case-Control Study

K. Kurnik, W. Kreuz, U. Nowak‐Göttl, 2005 .

Preliminary experiences with triple therapy including nelfinavir and two reverse transcriptase inhibitors in previously untreated HIV-infected children.

W. Kreuz, R. Linde, M. Funk, 1999, AIDS.

Epidemiology of Inhibitor Development in Haemophilia A Patients Treated with Virus– Inactivated Plasma–Derived Clotting Factor Concentrates

C. Escuriola-Ettingshausen, W. Kreuz, B. Kornhuber, 1999, Vox Sanguinis.

Human protein C concentrate in the treatment of purpura fulminans: a retrospective analysis of safety and outcome in 94 pediatric patients

F. Wong, U. Mansmann, W. Kreuz, 2010, Critical care.

Treatment of diarrhoea in human immunodeficiency virus-infected patients with immunoglobulins from bovine colostrum

E. Helm, I. Schedel, W. Kreuz, 1992, The clinical investigator.

Prophylaxis with FEIBA in paediatric patients with haemophilia A and inhibitors

C. Escuriola-Ettingshausen, N. Ewing, W. Kreuz, 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

Modified magnetic resonance imaging score compared with orthopaedic and radiological scores for the evaluation of haemophilic arthropathy

T. Klingebiel, W. Kreuz, C. Escuriola, 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

Humoral immune responsiveness to a defined epitope on factor VIII before and after B cell ablation with rituximab.

U. Dietrich, C. Königs, T. Klingebiel, 2008, Molecular immunology.

When should prophylactic treatment in patients with haemophilia A and B start?— The German experience

C. Kessler, C. Escuriola-Ettingshausen, W. Kreuz, 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

Prevention of joint damage in hemophilic children with early prophylaxis

W. Kreuz, C. Escuriola Ettingshausen, M. Funk, 1999, Der Orthopäde.

Long-term aspects of hemophilia B treatment: part I—role for prophylaxis

C. E. Ettingshausen, W. Kreuz, 2004, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Radiological and orthopedic score in pediatric hemophilic patients with early and late prophylaxis

C. Escuriola-Ettingshausen, W. Kreuz, M. Funk, 1998, Annals of Hematology.

Radiological score in paediatric haemophilic patients with early and late onset of factor VIII-prophylaxis.

S. Böttger, W. Kreuz, M. Funk, 1996, Thrombosis and haemostasis.

Review of Data for Monoclonal Antibody-purified Plasma-derived Factor IX

M. Morfini, W. Kreuz, 2011 .

First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study

J. Oldenburg, V. Jiménez‐Yuste, A. Pavlova, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Haemophilia and thrombophilia

K. Kurnik, W. Kreuz, C. Escuriola, 2003, Hämostaseologie.

Treatment patterns and cost‐of‐illness of severe haemophilia in patients with inhibitors in Germany

K. Kurnik, W. Schramm, G. Auerswald, 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

Epidemiology of Inhibitors in Haemophilia A

C. Escuriola-Ettingshausen, W. Kreuz, B. Kornhuber, 1996, Vox sanguinis.

C1‐inhibitor concentrate for individual replacement therapy in patients with severe hereditary angioedema refractory to danazol prophylaxis

T. Klingebiel, W. Kreuz, E. Aygören‐Pürsün, 2009, Transfusion.

[Evaluation of haemophilic arthropathy--a comparison of MRI and Pettersson score].

W. Kreuz, M. Funk, H. Schmidt, 2002, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.

A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate®P/ Humate®‐P: History and clinical performance

P. Mannucci, G. Auerswald, M. Franchini, 2008, European journal of haematology. Supplementum.

Prevalence and outcome of intracranial haemorrhage in haemophiliacs – a survey of the paediatric group of the German Society of Thrombosis and Haemostasis (GTH)

W. Kreuz, H. Brackmann, G. Auerswald, 1999, European Journal of Pediatrics.

The Role of Age at First Exposure and Therapy Regimen on the Development of Neutralizing FVIII Antibodies in Hemophilia A.

T. Klingebiel, C. E. Ettingshausen, W. Kreuz, 2004 .

Valproate Therapy Induces von Willebrand Disease Type I

W. Kreuz, U. Nowak‐Göttl, I. Scharrer, 1992, Epilepsia.

Efficacy and tolerability of a pasteurised human fibrinogen concentrate in patients with congenital fibrinogen deficiency.

W. Kreuz, S. Haertel, E. Meili, 2005, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

Hereditary angioedema (HAE) in children and adolescents—a consensus on therapeutic strategies

D. Meyer‐Olson, V. Wahn, W. Aberer, 2012, European Journal of Pediatrics.

Asphyxiation by laryngeal edema in patients with hereditary angioedema.

K. Bork, W. Kreuz, R. Schopf, 2000, Mayo Clinic proceedings.

Treatment of consumption coagulopathy with antithrombin concentrate in children with acquired antithrombin deficiency – A feasibility pilot study

W. Kreuz, U. Nowak‐Göttl, W. Schneider, 1999, European Journal of Pediatrics.

Abdominal venous thrombosis in neonates and infants: role of prothrombotic risk factors - a multicentre case-control study. For the Childhood Thrombophilia Study Group.

R. Junker, K. Kurnik, W. Kreuz, 2000 .

Abdominal venous thrombosis in neonates and infants: role of prothrombotic risk factors – a multicentre case–control study

R. Junker, K. Kurnik, W. Kreuz, 2000, British journal of haematology.

Thrombolysis with recombinant tissue-type plasminogen activator in renal venous thrombosis in infancy

W. Kreuz, U. Nowak‐Göttl, D. Schwabe, 1992, The Lancet.

Thrombolysis in Newborns and Infants

R. Junker, W. Kreuz, S. Halimeh, 1999, Thrombosis and Haemostasis.

Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A

C. Rothschild, J. Gill, P. Larson, 2005, Thrombosis and Haemostasis.

[Prevention of joint damage in hemophilic children with early prophylaxis].

W. Kreuz, C. Escuriola Ettingshausen, M. Funk, 1999, Der Orthopade.

Inhibitor treatment by rituximabin congenital haemophilia A

W. Kreuz, C. Escuriola Ettingshausen, R. Linde, 2009, Hämostaseologie.

The Role of Therapy Regimen and Age at First Exposure on Inhibitor Development in Patients with Severe Hemophilia A

C. E. Ettingshausen, W. Kreuz, R. Linde, 2005 .

Variables that might affect the outcome of immune tolerance therapy in haemophiliacs with factor VIII inhibitors.

G. Auerswald, W. Kreuz, S. Ehrenforth, 1994, Thrombosis and haemostasis.

Inhibitor Incidence in Previously Untreated Patients (PUPs) with Hemophilia A and B. A Prospective Multi-Center Study of the Pediatric Committee of the German, Swiss and Austrian Society for Thrombosis and Hemostasis Research (GTH)

G. Auerswald, W. Kreuz, H. Lenk, 2006 .

Factor VIII inhibitors in haemophiliacs

W. Kreuz, S. Ehrenforth, I. Scharrer, 1992, The Lancet.

Successful treatment of patients with von Willebrand disease using a high-purity double-virus inactivated factor VIII/von Willebrand factor concentrate (Immunate).

G. Auerswald, W. Kreuz, H. Wolf, 2002, Seminars in thrombosis and hemostasis.

Immune tolerance induction with a factor VIII concentrate containing von Willebrand factor (Haemoctin SDH®) in 14 patients with severe haemophilia A

C. Escuriola-Ettingshausen, K. Kurnik, R. Klamroth, 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

Epitope Mapping during FVIII Inhibitor Elimination with Rituximab Reveals Conformational Epitopes on FVIII and Identifies Small Molecules Blocking Inhibitor and Targeting B Cells

U. Dietrich, C. Königs, T. Klingebiel, 2006 .

Detection of all anti‐factor VIII antibodies in haemophilia A patients by the Bethesda assay and a more sensitive immunoprecipitation assay

G. Auerswald, W. Kreuz, H. Lenk, 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

The immune tolerance induction (ITI) dose debate: does the International ITI Study provide a clearer picture?

C. E. Ettingshausen, W. Kreuz, C. Ettingshausen, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

Screening of F.VIII:C Antibodies by an Enzyme‐Linked Immunosorbent Assay

W. Kreuz, S. Ehrenforth, I. Scharrer, 1994, Vox sanguinis.

Detection of all anti-factor VIII antibodies in haemophilia A patients by the Bethesda assay and a more sensitive immunoprecipitation assay.

G. Auerswald, W. Kreuz, H. Lenk, 2001 .

Inhibitor Development in Previously Untreated Patients with Hemophilia A and B: A Prospective 23-Year Follow-Up

J. Oldenburg, C. E. Ettingshausen, W. Kreuz, 2001 .

Home therapy with intravenous human C1‐inhibitor in children and adolescents with hereditary angioedema

T. Klingebiel, W. Kreuz, E. Aygören‐Pürsün, 2012, Transfusion.

HAE international home therapy consensus document

M. Gompels, H. Farkas, M. Levi, 2010, Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology.

Pharmacokinetics and Tolerability of Factor XIII Concentrates Prepared from Human Placenta or Plasma: a Crossover Randomised Study

W. Kreuz, H. Brackmann, R. Zimmermann, 1995, Thrombosis and Haemostasis.

Therapy-resistant haemarthros in a patient with factor VIII inhibitor: successful treatment with recombinant factor VIIa

J. Oldenburg, W. Kreuz, S. Eber, 1999, European Journal of Pediatrics.

Identification of Inhibitor Epitopes in Acquired Hemophilia by Phage Display

C. Königs, W. Kreuz, M. Krause, 2007 .

Prevention of Hepatitis C Virus Infestion in Children with Haemophilia A and B and von Willebrand’s Disease

G. Auerswald, W. Kreuz, R. Linde, 1992, Thrombosis and Haemostasis.

Peptide mimotopes selected with HIV‐1‐blocking monoclonal antibodies against CCR5 represent motifs specific for HIV‐1 entry

J. Irving, U. Dietrich, C. Königs, 2007, Immunology and cell biology.

Absence of hepatitis A after treatment with pasteurised factor VIII concentrates in children with haemophilia A and von Willebrand disease

W. Kreuz, G. Auerswald, L. Gürtler, 1993, The Lancet.

Nelfinavir pharmacokinetics in HIV-infected children: a comparison of twice daily and three times daily dosing.

M. Kurowski, W. Kreuz, R. Linde, 2000, AIDS.

Low prevalence of hepatitis E virus antibodies in hepatitis C virus‐ positive patients with coagulation disorders

W. Kreuz, B. Kornhuber, D. Klarmann, 1995, Transfusion.

Therapie der chronischen Hepatitis-C-Infektion mit rekombinantem Interferon α bei Kindern, die über Blut oder Blutprodukte infiziert wurden

W. Kreuz, M. Roggendorf, S. Stöhr, 1994 .

Effect of first line therapy including efavirenz and two nucleoside reverse transcriptase inhibitors in HIV-infected children.

C. Königs, M. Stürmer, W. Kreuz, 2005, European journal of medical research.

Characterization of acute hereditary angioedema attacks during pregnancy and breast-feeding and their treatment with C1 inhibitor concentrate.

T. Klingebiel, W. Kreuz, E. Aygören‐Pürsün, 2010, American journal of obstetrics and gynecology.

haracterization of acute hereditary angioedema ttacks during pregnancy and breast-feeding nd their treatment with C 1 inhibitor concentrate

T. Klingebiel, W. Kreuz, E. Aygören‐Pürsün, 2022 .

Risk of angioedema following invasive or surgical procedures in HAE type I and II – the natural history

T. Klingebiel, W. Kreuz, E. Aygören‐Pürsün, 2013, Allergy.

Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.

William H. Yang, P. Keith, P. Schmid‐Grendelmeier, 2010, The New England journal of medicine.

Pharmacokinetics of plasma-derived C1-esterase inhibitor after subcutaneous versus intravenous administration in subjects with mild or moderate hereditary angioedema: the PASSION study

T. Rossmanith, M. Cicardi, W. Kreuz, 2013, Transfusion.

Functional C1-inhibitor diagnostics in hereditary angioedema: assay evaluation and recommendations.

H. Joller-jemelka, L. Truedsson, C. Hack, 2008, Journal of immunological methods.

Pharmacokinetic analysis of human plasma–derived pasteurized C1‐inhibitor concentrate in adults and children with hereditary angioedema: a prospective study

T. Klingebiel, W. Kreuz, E. Aygören‐Pürsün, 2010, Transfusion.

Mutational spectrum of the C1INH (SERPING1) gene in patients with hereditary angioedema

J. Oldenburg, K. Bork, W. Kreuz, 2008, Cytogenetic and Genome Research.

Prophylaxis of hereditary angioedema attacks: A randomized trial of oral plasma kallikrein inhibition with avoralstat.

W. Kreuz, E. Aygören‐Pürsün, M. Maurer, 2016, The Journal of allergy and clinical immunology.

On demand treatment and home therapy of hereditary angioedema in Germany - the Frankfurt experience

T. Klingebiel, W. Kreuz, E. Aygören‐Pürsün, 2010, Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology.

Characterization of prodromal symptoms in a large population of patients with hereditary angio‐oedema

W. Kreuz, M. Maurer, M. Magerl, 2014, Clinical and experimental dermatology.

Pharmacokinetic Berinert P Study Of Subcutaneous Versus Intravenous Administration In Subjects With Moderate Hereditary Angioedema - The Passion Study

T. Klingebiel, M. Cicardi, W. Kreuz, 2011 .

Review of the Long-Term Safety of a Human Pasteurized C1 Inhibitor Concentrate

K. Bork, W. Kreuz, G. Korger, 2012 .

BCX4161, an Oral Kallikrein Inhibitor, Showed Significant Benefits on Reducing Disease Burden and Improving Quality of Life in Subjects with Hereditary Angioedema in the Opus-1 Study

W. Kreuz, E. Aygören‐Pürsün, M. Maurer, 2015 .

Efficacy Correlates with Plasma Levels in Opus-1, a Proof-of-Concept Study of Oral Kallikrein Inhibitor BCX4161 As a Prophylaxis Against Attacks of Hereditary Angioedema (HAE)

W. Kreuz, E. Aygören‐Pürsün, M. Maurer, 2015 .

Interaction between $$C\bar 1$$ -INA, coagulation, fibrinolysis and kinin system in hereditary angioneurotic edema (HANE) and urticaria

K. Bork, W. Kreuz, G. Witzke, 2004, Archives of Dermatological Research.

Mutation Analysis in Hereditary Angioedema Identifies Patients at Risk for Developing Acute and Life Threatening Edema

J. Oldenburg, K. Bork, W. Kreuz, 2006 .

Concomitant Diseases In Patients With Hereditary Angioedema - An Analysis Of Two Patient Groups With Different Severity of HAE

T. Klingebiel, W. Kreuz, E. Aygören‐Pürsün, 2009 .

Mutation Analysis of the C1 Inhibitor Gene

J. Oldenburg, K. Bork, W. Kreuz, 2005 .

[Hereditary angioneurotic edema. Clinical picture, diagnosis, patient management and drug therapy].

K. Bork, W. Kreuz, G. Witzke, 2008, Deutsche medizinische Wochenschrift.

Does Early Clinical Manifestation of Hereditary Angioedema (HAE) Influence the Clinical Course of the Disease

T. Klingebiel, W. Kreuz, E. Aygören‐Pürsün, 2013 .

15 parameters of coagulation and fibrinolysis in children with type I diabetes mellitus (onset period).

W. Kreuz, U. Nowak‐Göttl, B. Kornhuber, 1991, Klinische Padiatrie.

Severe factor V deficiency presenting as subdural haematoma in the newborn

B. Zabel, W. Kreuz, S. Ehrenforth, 1998, European Journal of Pediatrics.

Inhibitors in children with severe haemophilia A treated with recombinant and plasmatic FVIII products

L. Brandão, K. Kurnik, C. E. Ettingshausen, 2010, Hämostaseologie.

Familial Elevated Factor VIII in Children With Symptomatic Venous Thrombosis and Post-Thrombotic Syndrome: Results of a Multicenter Study

R. Junker, R. Kelsch, A. Heinecke, 2006, Arteriosclerosis, thrombosis, and vascular biology.

Induction of von Willebrand disease type I by valproic acid

W. Kreuz, U. Nowak‐Göttl, I. Scharrer, 1990, The Lancet.

Prophylactic treatment with pasteurized C1-inhibitor in Hereditary Angioedema - A prospective 32 months follow-up

W. Kreuz, C. Heller, D. Fischer, 1999 .

CMV coinfection and disease progression in vertically acquired HIV infection

W. Kreuz, D. Mentzer, 1999, Archives of disease in childhood.

Central nervous system involvement of children with HIV infection.

J. Seeger, W. Kreuz, B. Schmitt, 1991, Developmental medicine and child neurology.

Hepatitis C and Pasteurised Factor VIII and IX Concentrates

G. Auerswald, H. Rabenau, L. Gürtler, 1995, Thrombosis and Haemostasis.

Patient-to-patient transmission of hepatitis C virus

G. Auerswald, G. Kaplanski, J. Briggs, 1995, The Lancet.

"Treating through" hypersensitivity to cotrimoxazole in children with HIV infection

W. Kreuz, M. Funk, B. Kornhuber, 1990, The Lancet.

Post-trauma coagulation and fibrinolysis in children suffering from severe cerebro-cranial trauma

W. Kreuz, U. Nowak‐Göttl, I. Scharrer, 1970, European Journal of Pediatrics.

Neonatal Sepsis: A Challenge in Hemostaseology

C. E. Ettingshausen, W. Kreuz, D. Fischer, 1999, Seminars in thrombosis and hemostasis.

Protein-C concentrate for meningococcal purpura fulminans

C. Escuriola-Ettingshausen, W. Kreuz, A. Veldman, 1998, The Lancet.

Molecular biology and clinical manifestation of hereditary factor VII deficiency.

G. Marx, H. Losonczy, W. Kreuz, 2000, Seminars in Thrombosis and Hemostasis.

Seroepidemiology of HTLV-III (LAV) in the Federal Republic of Germany

P. Wernet, E. Seifried, R. Kurth, 1985, Klinische Wochenschrift.

Patient-to-patient transmission of hepatitis C virus.

W. Kreuz, G. Auerswald, B. Kornhuber, 1995, Lancet.

Cytomegalovirus myelitis in perinatally acquired HIV.

W. Kreuz, R. Linde, M. Funk, 1993, Archives of disease in childhood.

Retrochorionic hematoma in congenital afibrinogenemia: Resolution with fibrinogen concentrate infusions

J. Oldenburg, T. Klingebiel, V. Ivaškevičius, 2007, American journal of hematology.

Individual Replacement Therapy (IRT) with a Pasteurized C1-Inhibitor Concentrate Compared to Prophylaxis with Danazol in Patients with Hereditary Angioedema (HAE) - a Prospective Study.

T. Klingebiel, W. Kreuz, I. Martínez-Saguer, 2004 .

Hepatitis C and pasteurized C1‐inhibitor concentrate

W. Kreuz, S. Ehrenforth, D. Klarmann, 1996, Transfusion.

ITI with a VWF-Stabilised FVIII Concentrate in Haemophilia A Patients with Inhibitors and a Poor Prognosis for ITI Success: Progress Report on octanate® in the Observational ObsITI Study,

C. Escuriola-Ettingshausen, V. Vdovin, N. Zozulya, 2011 .

A multi‐centre study of efficacy and safety of Intratect®, a novel intravenous immunoglobulin preparation

W. Kreuz, L. Maródi, T. Español, 2010, Clinical and experimental immunology.

Development of a quasispecies of human immunodeficiency virus type 1 in vivo.

M. Gahr, R. Kurth, K. Cichutek, 1992, Proceedings of the National Academy of Sciences of the United States of America.

[Activated protein C resistance and venous thrombophilia: molecular genetic prevalence study in the German population].

A. Ganser, W. Kreuz, S. Ehrenforth, 1999, Deutsche medizinische Wochenschrift.

25 years of safety experience with C1 inhibitor concentrate in treatment of acute hereditary angioedema attacks

K. Bork, W. Kreuz, S. Fremann, 2011 .

Localization and Characterization of Mutations Within the Factor VIII Gene in a Cohort of 212 Patients with Hemophilia A

J. Oldenburg, S. Rost, R. Schwaab, 2001 .

Thrombophilia in a Child with CDG-Syndrome Type I

W. Kreuz, M. Funk, B. Pötzsch, 1995, Thrombosis and Haemostasis.

First experience with pentamidine inhalation in human immunodeficiency virus-infected children

W. Kreuz, S. Ehrenforth, R. Linde, 1991, European Journal of Pediatrics.

Low incidence of genotypic and phenotypic resistance in paediatric HIV-infected patients on long-term first-line antiretroviral triple therapy.

T. Klingebiel, W. Kreuz, R. Linde, 2001, AIDS.

ALLERGY, ASTHMA & CLINICAL IMMUNOLOGY REVIEW Open Access

P. Keith, J. Bernstein, R. Schellenberg, 2022 .

Three Novel Microdeletions and the First Insertion / Deletion in Patients with Factor X Deficiency

J. M. Carrillo, W. Kreuz, K. Wulff, 2005 .

German recommendations for immune tolerance therapy in type A haemophiliacs with antibodies

W. Kreuz, H. Brackmann, G. Auerswald, 1999, Haemophilia : the official journal of the World Federation of Hemophilia.

Successful Treatment of Patients with von Willebrand Disease Using a High-Purity Double Virus Inactivated FVIII/vWF Concentrate (IMMUNATE)

G. Auerswald, W. Kreuz, H. Wolf, 2001 .

Molecular Genetic Analysis in Patients with Inherited Thrombophilia and Antithrombin, Protein C or Protein S Deficiency

J. Oldenburg, M. Watzka, W. Kreuz, 2005 .

Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.

William H. Yang, P. Keith, P. Schmid‐Grendelmeier, 2010, The New England journal of medicine.

Characterization of prodromal symptoms in a large population of patients with hereditary angio‐oedema

W. Kreuz, M. Maurer, M. Magerl, 2014, Clinical and experimental dermatology.

Inhibitor Incidence in Previously Untreated Patients (PUP) with Hemophilia A and B - a 10-Year-Follow up of the Prospective Multicenter Study.

W. Kreuz, G. Auerswald, H. Lenk, 2004 .

Human protein C concentrate in the treatment of purpura fulminans: a retrospective analysis of safety and outcome in 94 pediatric patients

F. Wong, U. Mansmann, W. Kreuz, 2010, Critical care.

Clinical Surveillance Program Of Pediatric Hereditary Angioedema (HAE) Patients Undergoing Home Treatment

T. Klingebiel, W. Kreuz, E. Aygören‐Pürsün, 2009 .

T. Klingebiel, W. Kreuz, I. Martínez-Saguer, 2008 .

Acquired C1-Inhibitor Deficiency - Report of 18 Cases

W. Kreuz, E. Aygören‐Pürsün, E. Rusicke, 2009 .